Concise drug review: pazopanib and axitinib.

@article{Geel2012ConciseDR,
  title={Concise drug review: pazopanib and axitinib.},
  author={Robin M. J. M. van Geel and Jos H. Beijnen and Jan H. M. Schellens},
  journal={The oncologist},
  year={2012},
  volume={17 8},
  pages={1081-9}
}
Pazopanib and axitinib are both U.S. Food and Drug Administration approved ATP-competitive inhibitors of the vascular endothelial growth factor receptor. Pazopanib and axitinib have been shown to be effective and tolerable treatment options for patients with metastatic renal cell cancer and therefore have enlarged the armamentarium for this disease. This concise drug review discusses the clinical benefits, clinical use, mechanism of action, bioanalysis, pharmacokinetics, pharmacogenetics… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 3 times over the past 90 days. VIEW TWEETS
26 Citations
42 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 26 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 42 references

Similar Papers

Loading similar papers…